36.9 C
Nicosia
Sunday, July 21, 2024

Cancer: Over 2,000 new targeted therapies under study

Must read

Καρκiνος: Πνω αεσσεμeνεραες πo μελeτη

125 new cancer treatments were approved in the last five years, 25 last year. Increase in pharmaceutical spending to $223 billion worldwide

About 32 million people are expected to be affected by cancer by 2050, with new cases increasing by 12 million people per year.

Global pharmaceutical spending on anticancer drugs will reach $223 billion in 2023, up $25 billion from 2022, and is expected to reach $409 billion by 2028.

Last year, 25 new active oncology substances were launched worldwide, bringing the total number of oncology drugs to 193, since 2014. However, these drugs are not available to all patients, internationally.

In terms of research programs, more than 2,000 oncology clinical studies were launched in 2023, with significant promise for cancer treatment, many of them using cell and gene therapies, linking antibodies to drugs, using antibodies that target multiple targets, and therapies that associated with radiation therapy.

Cancer treatments are increasing by 9% every year since 2019, but not all patients can get innovative treatments, as biomarkers that show which treatment is the best have not been adopted internationally. appropriate, and furthermore, not all states have the new treatments or the infrastructure needed to implement the most advanced of them.

Καρκiνοσ: Πνω α&pi 2,000 νεσευμεσθεεσπ μελeτ&eta?

New gene therapies are being studied for more anti-cancer applications

The latest study by the largest health research company IQVIA regarding “Global Trends in Oncology 2024 – Outlook to 2028” went into this impression. The report points out that the increasing incidence of the disease, the increasing number of patients entering treatment and the expected increase in expenditure in this area will trigger a series of complex challenges for many years to come.

As it is pointed out, the new oncological mechanisms used for the development of new treatments now constitute 25% of clinical studies, focusing on gene and cell therapies, the conjugation of antibodies with specialized therapeutic active substances, but also on multi-target antibodies (multispecific antibodies ). All of these are targeted therapies that utilize innovative mechanisms of action and have been used against cancer for the last decade.

The research

Clinical studies for hematological cancers declined by 17% in 2023, while for solid tumors clinical development studies remained stable, after peaking in 2021.

PD-1/PD-L1 checkpoint inhibitors, which have seen significant growth over the past decade, have grown by 29% over the past five years and have started to decline in recent years, showing their upward trajectory in the market, leading to turning to even newer molecules for that specific target.

The use of these inhibitors varies greatly between countries, with the US, Germany and France using two to three times as many checkpoint inhibitors per capita than the UK and South Korea.

Many of the major European countries have similar usage rates to other developed markets, such as the Nordic countries.

  • Emerging biopharmaceutical companies were responsible for 60% of oncology trials in 2023, up from 33% a decade ago.
  • Oncology trials by China-based companies have grown to 35% from just 5% before since a decade.
  • Cell and gene therapy studies are focused on CAR-T cell therapies, particularly in hematological cancers. More than 250 such clinical studies have started in 2023, with a growing number in solid tumors.
  • Conjugated antibodies approved worldwide reach 15, and new studies of them have increased at an average annual rate of 22% over the past five years.
  • Ten bispecific antibodies are on the market worldwide for oncology, with many being developed for solid tumors.
  • Combination radiation therapy treatments are being tested in a range of tumors, primarily prostate and neuroendocrine tumors.
  • Multiple innovative methods are rapidly evolving with significant potential both alone and especially in combination with each other.
  • Regulators and industry are pushing the boundaries around cancer drug development to accelerate solutions for patients . Evidence for the potential use of artificial intelligence is growing in this direction, as prospective researchers advance to clinical development.

New anticancer drugs

A total of 125 oncology new active substances have been released worldwide in the last 5 years – almost double the 67 new drugs in the immediately preceding five years – and 259 in a 20-year period. But the release of these new drugs did not happen in all the countries of the world.

Most oncology treatments are released in the USA, but in the last five years, China has surpassed it, making available 83 new drugs in the last five years, from 24 new treatments in 2014–2018. Of these 83 new drugs, 37 concerned only China, and have not been released in other countries.

Expenditure

Expenditure on cancer drugs will increase to $223 billion worldwide in 2023, with 74% concentrated in major developed markets (the United States, the Europe's four largest countries, the UK and Japan), which have remained stable over the past five years.

Spending growth in these major developed markets is expected to be similar over the next five years to the last five years, with the growth rate over the next five years to 2028 expected to range between 11-14% for both the US and the four largest European countries and the UK, while for Japan the growth rate is forecast to range between 4-7 %.

US spending on oncology increased from $99 billion in 2023, up from $65 billion in 2019. This amount represents 45% of global spending and in 2028 it is expected to increase to approximately 180 billion dollars.

source: in.gr

Source: 24h.com.cy

- Advertisement -AliExpress WW

More articles

- Advertisement -AliExpress WW

Latest article